Physician profile
Ellen Ritch
NPI 1700292281
$6,856.41
in general payments reported to CMS, 2019-2025
27 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.09 · 2022: $57.75 · 2023: $1,466 · 2024: $2,576 · 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,701.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.03 | 2023-2025 | |
| Alkermes, INC. | $984.22 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $656.34 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $565.64 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $461.11 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $419.29 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $397.13 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $323.68 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $196.92 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $190.29 | 2022-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $186.13 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $146.75 | 2023 | Uzedy |
| Bausch Health US, LLC | $126.41 | 2023-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $114.81 | 2024-2025 | Loreev Xr |
| Biogen, INC. | $105.29 | 2025 | Zurzuvae |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $79.06 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $73.93 | 2024-2025 | Ingrezza |
| Neos Therapeutics, Lp | $60.04 | 2023-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $53.63 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $45.11 | 2024 | |
| Supernus Pharmaceuticals, INC. | $41.51 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $32.87 | 2025 | Jornay Pm |
| Braeburn INC. | $29.99 | 2025 | Brixadi |
| Merck Sharp & Dohme LLC | $23.27 | 2025 | Zerbaxa |
| Lundbeck LLC | $19.09 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $13.73 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Ritch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.